<p>Pitcairn Co. 在最近向证券交易委员会的披露中表示，在第二季度将其在西方制药服务公司（NYSE:WST - 免费报告）的股份减少了 31.6%。该公司在此期间出售了 3,991 股后，持有 8,637 股这家医疗器械供应商的股票。Pitcairn Co. 在西方制药服务公司的持股在最近的报告期末价值为 1,890,000 美元。</p>
<ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
<p>其他几家机构投资者最近也对该股票的持仓进行了调整。Generation Investment Management LLP 在第二季度购买了西方制药服务公司的新股份，价值为 255,072,000 美元。Durable Capital Partners LP 在第一季度将其在西方制药服务公司的股份增加了 146.8%。Durable Capital Partners LP 现在持有 1,573,119 股这家医疗器械供应商的股票，价值为 352,190,000 美元，此前在上个季度又购买了 935,721 股。挪威银行在第二季度购买了西方制药服务公司的新股份，价值约为 200,813,000 美元。Kayne Anderson Rudnick Investment Management LLC 在第一季度将其在西方制药服务公司的股份增加了 57.8%。Kayne Anderson Rudnick Investment Management LLC 现在持有 997,882 股这家医疗器械供应商的股票，价值为 223,406,000 美元，此前在上个季度又购买了 365,575 股。最后，瑞银资产管理美洲有限公司的一个独立业务部门在第一季度将其在西方制药服务公司的持股增加了 43.5%。瑞银资产管理美洲有限公司的一个独立业务部门现在持有 1,134,706 股这家医疗器械供应商的股票，价值为 254,038,000 美元，此前在此期间又购买了 343,997 股。93.90% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师设定新的价格目标</h2>
<p>几位研究分析师最近对该股票发表了评论。Rothschild Redb 在 9 月 15 日的报告中将西方制药服务公司的股票评级上调至 “强力买入”。Cowen 在 10 月 29 日的研究报告中开始覆盖西方制药服务公司的股票，并给予 “买入” 评级。Rothschild &amp; Co Redburn 在 9 月 15 日的报告中开始覆盖西方制药服务公司的股票，设定了 “买入” 评级和 311.00 美元的目标价格。Evercore ISI 在 10 月 23 日的研究报告中将西方制药服务公司的股票目标价格从 350.00 美元上调至 390.00 美元，并给予该股票 “跑赢大盘” 的评级。最后，KeyCorp 在 10 月 24 日的研究报告中将西方制药服务公司的目标价格从 325.00 美元上调至 350.00 美元，并给予该公司 “增持” 评级。两位研究分析师对该股票给予了强力买入评级，八位给予了买入评级，四位给予了持有评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，平均目标价格为 342.20 美元。</p>
<ul>
<li>什么因素将推动标准普尔 500 指数今年的表现？</li>
</ul>
<p><strong>获取我们关于 WST 的最新报告</strong></p>
<h2>西方制药服务公司的价格表现</h2>
<p>WST 股票在周一开盘价为 267.03 美元。该公司的 50 日简单移动平均线为 273.72 美元，200 日简单移动平均线为 250.42 美元。该公司的市值为 192.1 亿美元，市盈率为 39.56，市盈增长比率为 4.14，贝塔值为 1.17。西方制药服务公司在过去 12 个月的最低价为 187.43 美元，最高价为 348.90 美元。该公司的流动比率为 2.87，速动比率为 2.18，债务与股本比率为 0.07。</p>
<ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
<p>西方制药服务公司（NYSE:WST - 获取免费报告）最近在 10 月 23 日发布了季度财报。这家医疗器械供应商报告季度每股收益为 1.96 美元，超出分析师一致预期的 1.67 美元，超出幅度为 0.29 美元。该公司季度收入为 8.046 亿美元，而分析师预期为 7.8842 亿美元。西方制药服务公司的净利润率为 16.29%，股本回报率为 18.16%。该公司的收入较去年同期增长了 7.7%。在去年同期，该公司每股收益为 1.85 美元。西方制药服务公司已将其 2025 财年的指导目标设定为每股收益 7.060-7.110 美元。股票研究分析师预计西方制药服务公司将在当前财年发布每股收益 6.62 美元。</p>
<h2>西方制药服务公司宣布分红</h2>
<p>该公司还最近披露了一项季度分红，将于 2 月 4 日（星期三）支付。1 月 28 日（星期三）的股东将获得每股 0.22 美元的分红。除息日为 1 月 28 日（星期三）。这代表着每年 0.88 美元的分红，收益率为 0.3%。西方制药服务公司的派息比率目前为 13.04%。</p>
<h2>西方制药服务公司简介</h2>
<p>（免费报告）</p>
<p>西方制药服务公司设计、制造和销售用于注射药物和医疗保健产品的封闭和输送系统，业务覆盖美洲、欧洲、中东、非洲和亚太地区。该公司分为两个部门，专有产品和合同制造产品。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比西方制药服务公司更好</li>
<li>3 只小盘股具有巨大的回报潜力</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了游戏</li>
<li>纽约证券交易所和纳斯达克的区别，以及这对投资者的重要性</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>哪些华尔街分析师最准确？</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在西方制药服务公司吗？</h2>
<p>在你考虑西方制药服务公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而西方制药服务公司并不在名单上。</p>
<p>虽然西方制药服务公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

西氏医药服务

<p>Pitcairn Co. 在第二季度减少了对西氏医药服务的持股比例，降幅为 31.6%，目前持有 8,637 股，市值为 189 万美元。其他机构投资者如 Generation Investment 和挪威银行则增加了他们的持股。分析师们对该股票给予了一致的 “适度买入” 评级，目标价为 342.20 美元。西氏医药服务报告了第三季度每股收益为 1.96 美元，超出预期，营收同比增长 7.7%。公司已将 2025 财年的每股收益指引设定在 7.060-7.110 之间</p>

<p>Pitcairn Co. lowered its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 31.6% during the second quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 8,637 shares of the medical instruments supplier's stock after selling 3,991 shares during the period. Pitcairn Co.'s holdings in West Pharmaceutical Services were worth $1,890,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Pitcairn Co. 在最近向证券交易委员会的披露中表示，在第二季度将其在西方制药服务公司（NYSE:WST - 免费报告）的股份减少了 31.6%。该公司在此期间出售了 3,991 股后，持有 8,637 股这家医疗器械供应商的股票。Pitcairn Co. 在西方制药服务公司的持股在最近的报告期末价值为 1,890,000 美元。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
</div><p>Several other institutional investors also recently made changes to their positions in the stock. Generation Investment Management LLP purchased a new position in shares of West Pharmaceutical Services in the 2nd quarter worth $255,072,000. Durable Capital Partners LP increased its stake in West Pharmaceutical Services by 146.8% during the first quarter. Durable Capital Partners LP now owns 1,573,119 shares of the medical instruments supplier's stock worth $352,190,000 after acquiring an additional 935,721 shares during the last quarter. Norges Bank purchased a new position in shares of West Pharmaceutical Services in the 2nd quarter worth about $200,813,000. Kayne Anderson Rudnick Investment Management LLC lifted its stake in shares of West Pharmaceutical Services by 57.8% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 997,882 shares of the medical instruments supplier's stock valued at $223,406,000 after purchasing an additional 365,575 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of West Pharmaceutical Services by 43.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,134,706 shares of the medical instruments supplier's stock worth $254,038,000 after purchasing an additional 343,997 shares during the period. 93.90% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者最近也对该股票的持仓进行了调整。Generation Investment Management LLP 在第二季度购买了西方制药服务公司的新股份，价值为 255,072,000 美元。Durable Capital Partners LP 在第一季度将其在西方制药服务公司的股份增加了 146.8%。Durable Capital Partners LP 现在持有 1,573,119 股这家医疗器械供应商的股票，价值为 352,190,000 美元，此前在上个季度又购买了 935,721 股。挪威银行在第二季度购买了西方制药服务公司的新股份，价值约为 200,813,000 美元。Kayne Anderson Rudnick Investment Management LLC 在第一季度将其在西方制药服务公司的股份增加了 57.8%。Kayne Anderson Rudnick Investment Management LLC 现在持有 997,882 股这家医疗器械供应商的股票，价值为 223,406,000 美元，此前在上个季度又购买了 365,575 股。最后，瑞银资产管理美洲有限公司的一个独立业务部门在第一季度将其在西方制药服务公司的持股增加了 43.5%。瑞银资产管理美洲有限公司的一个独立业务部门现在持有 1,134,706 股这家医疗器械供应商的股票，价值为 254,038,000 美元，此前在此期间又购买了 343,997 股。93.90% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>Several research analysts recently commented on the stock. Rothschild Redb upgraded shares of West Pharmaceutical Services to a &#34;strong-buy&#34; rating in a report on Monday, September 15th. Cowen started coverage on shares of West Pharmaceutical Services in a research note on Wednesday, October 29th. They issued a &#34;buy&#34; rating on the stock. Rothschild &amp; Co Redburn assumed coverage on shares of West Pharmaceutical Services in a report on Monday, September 15th. They set a &#34;buy&#34; rating and a $311.00 target price on the stock. Evercore ISI upped their price target on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, October 23rd. Finally, KeyCorp raised their price objective on West Pharmaceutical Services from $325.00 to $350.00 and gave the company an &#34;overweight&#34; rating in a research report on Friday, October 24th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $342.20.</p>
<div class="lb-trans"><p>几位研究分析师最近对该股票发表了评论。Rothschild Redb 在 9 月 15 日的报告中将西方制药服务公司的股票评级上调至 “强力买入”。Cowen 在 10 月 29 日的研究报告中开始覆盖西方制药服务公司的股票，并给予 “买入” 评级。Rothschild &amp; Co Redburn 在 9 月 15 日的报告中开始覆盖西方制药服务公司的股票，设定了 “买入” 评级和 311.00 美元的目标价格。Evercore ISI 在 10 月 23 日的研究报告中将西方制药服务公司的股票目标价格从 350.00 美元上调至 390.00 美元，并给予该股票 “跑赢大盘” 的评级。最后，KeyCorp 在 10 月 24 日的研究报告中将西方制药服务公司的目标价格从 325.00 美元上调至 350.00 美元，并给予该公司 “增持” 评级。两位研究分析师对该股票给予了强力买入评级，八位给予了买入评级，四位给予了持有评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，平均目标价格为 342.20 美元。</p>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>什么因素将推动标准普尔 500 指数今年的表现？</li>
</ul>
</div><p><strong>Get Our Latest Report on WST</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 WST 的最新报告</strong></p>
</div><h2>West Pharmaceutical Services Price Performance</h2>
<div class="lb-trans"><h2>西方制药服务公司的价格表现</h2>
</div><p>Shares of WST stock opened at $267.03 on Monday. The firm has a fifty day simple moving average of $273.72 and a 200-day simple moving average of $250.42. The company has a market capitalization of $19.21 billion, a PE ratio of 39.56, a price-to-earnings-growth ratio of 4.14 and a beta of 1.17. West Pharmaceutical Services, Inc. has a twelve month low of $187.43 and a twelve month high of $348.90. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.07.</p>
<div class="lb-trans"><p>WST 股票在周一开盘价为 267.03 美元。该公司的 50 日简单移动平均线为 273.72 美元，200 日简单移动平均线为 250.42 美元。该公司的市值为 192.1 亿美元，市盈率为 39.56，市盈增长比率为 4.14，贝塔值为 1.17。西方制药服务公司在过去 12 个月的最低价为 187.43 美元，最高价为 348.90 美元。该公司的流动比率为 2.87，速动比率为 2.18，债务与股本比率为 0.07。</p>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its quarterly earnings data on Thursday, October 23rd. The medical instruments supplier reported $1.96 EPS for the quarter, topping analysts' consensus estimates of $1.67 by $0.29. The firm had revenue of $804.60 million for the quarter, compared to analyst estimates of $788.42 million. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The firm's revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. Equities research analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>西方制药服务公司（NYSE:WST - 获取免费报告）最近在 10 月 23 日发布了季度财报。这家医疗器械供应商报告季度每股收益为 1.96 美元，超出分析师一致预期的 1.67 美元，超出幅度为 0.29 美元。该公司季度收入为 8.046 亿美元，而分析师预期为 7.8842 亿美元。西方制药服务公司的净利润率为 16.29%，股本回报率为 18.16%。该公司的收入较去年同期增长了 7.7%。在去年同期，该公司每股收益为 1.85 美元。西方制药服务公司已将其 2025 财年的指导目标设定为每股收益 7.060-7.110 美元。股票研究分析师预计西方制药服务公司将在当前财年发布每股收益 6.62 美元。</p>
</div><h2>West Pharmaceutical Services Announces Dividend</h2>
<div class="lb-trans"><h2>西方制药服务公司宣布分红</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 4th. Shareholders of record on Wednesday, January 28th will be issued a dividend of $0.22 per share. The ex-dividend date is Wednesday, January 28th. This represents a $0.88 annualized dividend and a yield of 0.3%. West Pharmaceutical Services's payout ratio is currently 13.04%.</p>
<div class="lb-trans"><p>该公司还最近披露了一项季度分红，将于 2 月 4 日（星期三）支付。1 月 28 日（星期三）的股东将获得每股 0.22 美元的分红。除息日为 1 月 28 日（星期三）。这代表着每年 0.88 美元的分红，收益率为 0.3%。西方制药服务公司的派息比率目前为 13.04%。</p>
</div><h2>West Pharmaceutical Services Company Profile</h2>
<div class="lb-trans"><h2>西方制药服务公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.</p>
<div class="lb-trans"><p>西方制药服务公司设计、制造和销售用于注射药物和医疗保健产品的封闭和输送系统，业务覆盖美洲、欧洲、中东、非洲和亚太地区。该公司分为两个部门，专有产品和合同制造产品。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>3 Small Caps With Big Return Potential</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>How the NYSE and NASDAQ are Different, Why That Matters to Investors</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比西方制药服务公司更好</li>
<li>3 只小盘股具有巨大的回报潜力</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了游戏</li>
<li>纽约证券交易所和纳斯达克的区别，以及这对投资者的重要性</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>哪些华尔街分析师最准确？</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在西方制药服务公司吗？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑西方制药服务公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而西方制药服务公司并不在名单上。</p>
</div><p>While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然西方制药服务公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Pitcairn 公司出售了西氏医药服务公司（West Pharmaceutical Services, Inc.）的股票，股票代码为$WST